Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Gastroenterology Research and Practice
Volume 2017 (2017), Article ID 2019802, 6 pages
https://doi.org/10.1155/2017/2019802
Clinical Study

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin

1Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2Department of Gastroenterology, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan
3Advanced Medical Research Center, Yokohama City University, Yokohama, Japan

Correspondence should be addressed to Shin Maeda; pj.ca.uc-amahokoy@adeams

Received 28 June 2017; Accepted 11 September 2017; Published 18 October 2017

Academic Editor: Tatsuya Toyokawa

Copyright © 2017 Soichiro Sue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. C. Lee, T. H. Chiang, C. K. Chou et al., “Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis,” Gastroenterology, vol. 150, no. 5, pp. 1113–1124.e5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. J. L. Ma, L. Zhang, L. M. Brown et al., “Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality,” JNCI: Journal of the National Cancer Institute, vol. 104, no. 6, pp. 488–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Herrero, J. Y. Park, and D. Forman, “The fight against gastric cancer - the IARC Working Group report,” Best Practice & Research Clinical Gastroenterology, vol. 28, no. 6, pp. 1107–1114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Y. Wu, J. M. Liou, and D. Y. Graham, “Evidence-based recommendations for successful Helicobacter pylori treatment,” Expert Review of Gastroenterology & Hepatology, vol. 8, no. 1, pp. 21–28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Y. Graham, H. Lu, and Y. Yamaoka, “A report card to grade Helicobacter pylori therapy,” Helicobacter, vol. 12, no. 4, pp. 275–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Yuan, A. C. Ford, K. J. Khan et al., “Optimum duration of regimens for Helicobacter pylori eradication,” The Cochrane Database of Systematic Reviews, vol. 12, article CD008337, 2013. View at Publisher · View at Google Scholar
  8. M. Rodriguez-Torres, R. Salgado-Mercado, C. F. Rios-Bedoya et al., “High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin,” Digestive Diseases and Sciences, vol. 50, no. 4, pp. 634–639, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Gisbert, J. L. Gisbert, S. Marcos, D. Olivares, and J. M. Pajares, “Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 10, pp. 1041–1046, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Gisbert, ““Rescue” regimens after Helicobacter pylori treatment failure,” World Journal of Gastroenterology, vol. 14, no. 35, pp. 5385–5402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Furuta, M. Sugimoto, M. Yamade et al., “Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin,” Internal Medicine, vol. 53, no. 6, pp. 571–575, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Liou, Y. J. Fang, C. C. Chen et al., “Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial,” Lancet, vol. 388, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Murakami, Y. Sakurai, M. Shiino, N. Funao, A. Nishimura, and M. Asaka, “Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study,” Gut, vol. 65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Gisbert, L. Gonzalez, X. Calvet et al., “Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 10, pp. 1319–1328, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Vaira, J. Holton, M. Menegatti et al., “Invasive and non-invasive tests for Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 14, Supplement 3, pp. 13–22, 2000. View at Publisher · View at Google Scholar
  16. J. P. Gisbert, F. de la Morena, and V. Abraira, “Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 101, no. 8, pp. 1921–1930, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. McNicholl, P. M. Linares, O. P. Nyssen, X. Calvet, and J. P. Gisbert, “Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 36, no. 5, pp. 414–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sue, H. Kuwashima, Y. Iwata et al., “The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a rrospective multi-center cohort study on Helicobacter pylori eradication,” Internal Medicine, vol. 56, no. 11, pp. 1277–1285, 2017. View at Publisher · View at Google Scholar
  19. M. P. Dore, G. Leandro, G. Realdi, A. R. Sepulveda, and D. Y. Graham, “Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach,” Digestive Diseases and Sciences, vol. 45, no. 1, pp. 68–76, 2000. View at Google Scholar
  20. Y. Hori, A. Imanishi, J. Matsukawa et al., “1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases,” The Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 231–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Sakurai, Y. Mori, H. Okamoto et al., “Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study,” Alimentary Pharmacology & Therapeutics, vol. 42, no. 6, pp. 719–730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Sachs, K. Meyer-Rosberg, D. R. Scott, and K. Melchers, “Acid, protons and Helicobacter pylori,” The Yale Journal of Biology and Medicine, vol. 69, no. 3, pp. 301–316, 1996. View at Google Scholar
  23. T. Furuta, M. Sugimoto, C. Kodaira et al., “Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan,” Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 487–493, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Georgopoulos, E. Xirouchakis, B. Martinez-Gonzales et al., “Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area,” European Journal of Internal Medicine, vol. 32, pp. 84–90, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. M. P. Dore, H. Lu, and D. Y. Graham, “Role of bismuth in improving Helicobacter pylori eradication with triple therapy,” Gut, vol. 65, no. 5, pp. 870–878, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Muranaka, H. Okumura, K. Takeda, K. Koizumi, and H. Igarashi, “Population studies on drug hypersensitivities,” Acta Allergologica, vol. 28, no. 1, pp. 50–61, 1973. View at Publisher · View at Google Scholar
  27. F. Harandian, D. Pham, and M. Ben-Shoshan, “Positive penicillin allergy testing results: a systematic review and meta-analysis of papers published from 2010 through 2015,” Postgraduate Medicine, pp. 1–6, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ono, M. Kato, S. Nakagawa, K. Mabe, and N. Sakamoto, “Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin,” Helicobacter, vol. 22, no. 3, article e12374, 2017. View at Publisher · View at Google Scholar